Cingulate Inc

$4.12
(as of Jun 23, 10:42 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Cingulate Inc

Stock Price
$4.12
Ticker Symbol
CING
Exchange
NASDAQ

Industry Information for Cingulate Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Cingulate Inc

Website
https://www.cingulate.com
Country
USA
Full Time Employees
13

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Fundamentals for Cingulate Inc

Market Capitalization
$18,893,408
EBITDA
$-15,748,010
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-4.03
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
4,245,710
Percent Owned by Insiders
2.40%
Percent Owned by Institutions
3.22%
52-Week High
52-Week Low

Technical Indicators for Cingulate Inc

50-Day Moving Average
200-Day Moving Average
RSI
48.28
ATR
0.35

Analyst Ratings for Cingulate Inc

Strong Buy
1
Buy
3
Hold
0
Sell
0
Strong Sell
0

News About Cingulate Inc

May 8, 2025, 4:30 PM EST
Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 See more.
Mar 26, 2025, 5:00 PM EST
In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission See more.
Dec 28, 2023, 2:54 AM EST
Investing.com -- U.S. futures traded largely unchanged Thursday, with investors largely shutting up shop as a positive year on Wall Street draws near to a close. See more.
Nov 13, 2023, 4:15 PM EST
Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity See more.